




A monthly report summarizing the Life Science transactions and trends in Washington State.


Washington State Transactions

Washington State Transactions by Sector



Number of Deals per Sector

*As of 1/29/2021



Monthly Highlights

HIGHLIGHTS

- AbSci, based in Vancouver, WA, announced acquisition of San Diego-based Denovium [www.denovium.com] to expand AbSci’s synthetic biology platform. Denovium uses a de novo approach and a deep learning platform for genome annotation and protein discovery. ([Geekwire](#))
- AltPep Corporation raised \$23.15M in a series A financing round to take their breakthrough amyloid targeting platform to development. AltPep has three targets, based on technology developed at a University of Washington lab: early diagnostic for Alzheimer’s Disease, anti-biofilm therapies and coating and disease-modifying therapeutics. ([Biospace](#); [AltPep](#))
- Parse Biosciences, formerly known as Split Biosciences, announced \$7M raise to support growth of its single cell sequencing technology. Parse Biosciences provides researchers with scalable and flexible single cell sequencing solutions. (full press release [Parse Biosciences](#))

This report is prepared by Laura Sconyers, Manager of Entrepreneurship. Questions or comments? Contact laura@lswinstitute.org.

**The data in this report are sourced from Pitchbook, Inc. and other publicly disclosed information. It is not independently verified by Life Science Washington Institute. Grants are not reported in this summary.



Washington Life Science Transactions

<u>Date</u>	<u>Company</u>	<u>Type</u>	<u>Amount</u>	<u>Location</u>
1/12/21	AltPep	Equity	\$23,150,000	Mercer Island
1/26/21	Parse BioSciences	Equity	\$7,560,000	Seattle